Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC extends comment period

This article was originally published in The Tan Sheet

Executive Summary

FTC grants a 90-day extension of the March 19 deadline for comments related to the commission's Guides Concerning the Use of Endorsements and Testimonials in Advertising and two consumer surveys it commissioned. The Electronic Retailing Association said it needs more time to evaluate the two reports and compile member opinions on the subject, FTC states. The new deadline for comments is June 18, according to FTC. The commission published the results of the two commissioned studies on efficacy of testimonial ads' disclosure statements in January. The studies found dietary supplements' disclosure statements are largely ineffective in helping consumers understand efficacy claims communicated in a testimonial advertisement (1"The Tan Sheet" Jan. 22, 2007, p. 10)....

You may also be interested in...

Disclosure Statements In Testimonial Ads Largely Ineffective – FTC Studies

Results from two studies funded by the Federal Trade Commission show disclosure statements for dietary supplements are largely ineffective in helping consumers understand product efficacy claims after they view testimonial advertisements

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Shuttered US Supplement Firm Meets Recall Deadline, But Schumer Says FDA Late Cleaning Up Industry

While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts